Shukra Pharmaceuticals Limited
All news and filings related to Shukra Pharmaceuticals Limited.
View all news & filings- Medium impact
Shukra Pharmaceuticals Approves Object Clause Amendment and Name Change to Shukra Medtech
Shukra Pharmaceuticals Limited shareholders approved a name change to Shukra Medtech Limited and an amendment to the object clause of the Memorandum of Association via remote e-voting. Both resolutions passed with over 99.9% of votes in favor. The voting concluded on September 26, 2026.
Read the summary - Medium impact
Shukra Pharmaceuticals Holds 33rd AGM on Sep 28, 2026, Approves Dividend
Shukra Pharmaceuticals Limited held its 33rd AGM on September 28, 2026. The meeting approved the final dividend for FY25-26 and re-appointed Ms. Sanskruti Patel as Director. Mr. Dinesh Chauhan's appointment as Independent Director was also regularized. Voting results will be announced within 48 hours.
Read the summary - Low impact
Shukra Pharmaceuticals Closes Trading Window for Q2 FY27 Results
Shukra Pharmaceuticals is closing its trading window from October 1, 2026, until 48 hours post-declaration of Q2 FY27 results. This is to prevent insider trading. The board meeting date for results approval will be announced later.
Read the summary - Low impact
Shukra Pharmaceuticals sets Sep 21, 2026 as Record Date for Final Dividend of ₹0.01
Shukra Pharmaceuticals has set September 21, 2026, as the Record Date for its Final Dividend. Shareholders are eligible for ₹0.01 per equity share for FY 2025-26, subject to approval at the AGM on September 28, 2026.
Read the summary - Low impact
Shukra Pharmaceuticals to hold 33rd AGM on Sep 28, 2026, to approve FY26 results and declare dividend
Shukra Pharmaceuticals Limited will hold its 33rd AGM on September 28, 2026, via Video Conference. The agenda includes adopting FY26 financial statements and approving a 1% final dividend. Ms. Sanskruti Patel's re-appointment as Director and Mr. Dinesh Chauhan's regularization as Independent Director are also on the agenda.
Read the summary - Low impact
Shukra Pharmaceuticals Reschedules 33rd AGM to September 28, 2026
Shukra Pharmaceuticals Limited has rescheduled its 33rd Annual General Meeting (AGM) to September 28, 2026. The book closure dates are revised to September 22-28, 2026. The meeting will be held via Video Conference/Other Audio-Visual Means.
Read the summary - Low impact
Shukra Pharmaceuticals Fixes Sept 21 as Record Date for Final Dividend
Shukra Pharmaceuticals has set September 21, 2026, as the Record Date for its final dividend of ₹0.01 per equity share for FY 2025-26. The dividend is subject to approval at the 33rd AGM on September 28, 2026.
Read the summary - Medium impact
Shukra Pharmaceuticals Allots 11.73 Lakh Equity Shares on Warrant Conversion
Shukra Pharmaceuticals allotted 11.73 lakh equity shares on September 02, 2026, upon conversion of warrants by Navkar Surgical Gujarat Limited. The conversion raised ₹3.13 crore. This increases the company's paid-up capital to ₹44.08 crore. Remaining 17.35 lakh warrants are outstanding.
Read the summary - Low impact
Shukra Pharmaceuticals Ltd. Publishes Newspaper Advertisement for Postal Ballot Notice
Shukra Pharmaceuticals Ltd. published a newspaper advertisement on August 31, 2026, for its postal ballot notice. E-voting is open from August 28 to September 26, 2026. Results will be announced by September 25, 2026.
Read the summary - Medium impact
Shukra Pharmaceuticals to seek shareholder approval for name change and MOA alteration
Shukra Pharmaceuticals is conducting a postal ballot for shareholders to approve a name change to 'Shukra MedTech Limited' and an alteration of its MOA to include MedTech and healthcare technology businesses. E-voting will take place from August 28, 2026, to September 26, 2026.
Read the summary - Medium impact
Shukra Pharmaceuticals to change name to Shukra Medtech Limited; AGM on Sep 25
Shukra Pharmaceuticals Limited approved changing its name to Shukra Medtech Limited, subject to approvals. The company will alter its MOA to reflect the new focus. The 33rd AGM is scheduled for September 25, 2026, with the Register of Members closed from September 19-25.
Read the summary - Medium impact
Shukra Pharmaceuticals Lists on NSE, Focuses on MedTech and AI
Shukra Pharmaceuticals Limited's shares are now listed on both BSE and NSE, following its listing on the National Stock Exchange on August 14, 2026. The company's strategy emphasizes Medical Technology, AI, and innovation in healthcare for future growth.
Read the summary - Medium impact
Shukra Pharmaceuticals to change name to Shukra Medtech Limited, expands into Medical Technology
Shukra Pharmaceuticals Limited will change its name to Shukra Medtech Limited. The company's Board of Directors approved expanding its business scope to include Medical Technology (MedTech). This strategic expansion is subject to shareholder and regulatory approvals.
Read the summary - High impact
Shukra Pharma inks JV term sheet with Borns Medical Robotics for AI surgical robots
Shukra Pharmaceuticals and Borns Medical Robotics signed a Term Sheet for a strategic joint venture, B&S Robotics Private Limited, to design, manufacture, and distribute AI-enabled surgical robotic systems in India and APAC. Shukra will hold 60% and Borns 40%. Definitive agreements are expected within 120 days.
Read the summary - Medium impact
Shukra Pharmaceuticals Lists on NSE, Enhancing Liquidity and Investor Access
Shukra Pharmaceuticals Limited shares listed on NSE on August 14, 2026. The dual listing on NSE and BSE aims to boost liquidity and expand the investor base. The reference price on NSE was set by BSE's closing price on August 13, 2026.
Read the summary - Medium impact
Shukra Pharma Direct Lists on NSE, Trading Begins August 14, 2026
Shukra Pharmaceuticals Limited has been approved for direct listing on the National Stock Exchange (NSE), with trading starting August 14, 2026. This dual-listing strategy aims to increase visibility and market liquidity. The company's shares will continue trading on the BSE.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio